Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to reduce pancreatitis risk after common bile duct procedure

NCT ID NCT07244432

Knowledge-focused Sponsor: Branislav Kuncak Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 2 times

Summary

This observational study will monitor 1,000 patients in Slovakia and Czechia who undergo ERCP, a procedure to treat bile duct problems. The main goal is to track how often pancreatitis occurs after the procedure and whether hospitals are following recommended prevention steps. The findings could help improve patient safety and reduce complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help hospitals better prevent pancreatitis after ERCP by showing which prevention methods work best in real-world practice.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to other regions or healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,135 people

The number who actually took part.

Started

Dec 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All consecutive adults undergoing ERCP at participating centers. Selected ERCP centers within the Slovakia and Czechia. The centers selected for this study are those that expressed interest in participating based on our yet unpublished 2024 survey, which aimed to assess how ERCP quality parameters were monitored and how prophylactic measures for PEP were implemented across centers. A total of 26 ERCP centers participated in the survey, including 14 from Slovakia and 12 from Czechia. Centers that expressed interest, as well as all remaining ERCP-performing centers in Slovakia and several in Czechia, were subsequently contacted by email with information about the study and invited to participate.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ERCP in a patient with a native papilla (first ERCP) or repeat ERCP in a patient with previous failed cannulation attempt. * Age at least 18 years at the time of ERCP. * Signed informed consent. Exclusion Criteria: * Previous papillotomy, papilla dilation, or sphincteroplasty. * Rendez-vous cannulation technique. * ERCP not performed due to insufficient patient cooperation. * ERCP terminated before cannulation due to sedation/anesthesia-related complications. * Failure to reach the Vater's or minor papilla (e.g. duodenal stenosis). * Acute biliary pancreatitis. * Altered anatomy that prevents reaching the papilla with a standard duodenoscope (e.g. Roux-en-Y).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERCP are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatitis acute pancreatitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ERCP Pancreatitis, acute Prophylaxis

Contacts and locations

Locations

  • Bory Hospital

    Bratislava, Slovakia

  • F.D. Roosevelt University Hsopital

    Banská Bystrica, Slovakia

  • Faculty Hospital J.A.Reiman Prešov

    Prešov, Slovakia

  • Faculty Hospital Trenčín

    Trenčín, Slovakia

  • Faculty Hospital Trnava

    Trnava, Slovakia

  • Faculty Hospital Žilina

    Žilina, Slovakia

  • Hospital Poprad

    Poprad, Slovakia

  • Klinika Orbis

    Nitra, Slovakia

  • National Oncology Institute

    Bratislava, Slovakia

  • Oblastní Nemocnice Příbram, a.s.

    Příbram, Czechia

  • University Hospital

    Bratislava, Slovakia

  • University Hospital - St. Michael's Hospital, Bratislava

    Bratislava, 81108, Slovakia

  • University Hospital Martin

    Martin, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.